McBride William H, Iwamoto Keisuke S, Syljuasen Randi, Pervan Milena, Pajonk Frank
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Oncogene. 2003 Sep 1;22(37):5755-73. doi: 10.1038/sj.onc.1206676.
In the last few years, the ubiquitin(Ub)/proteasome system has become increasingly recognized as a controller of numerous physiological processes, including signal transduction, DNA repair, chromosome maintenance, transcriptional activation, cell cycle progression, cell survival, and certain immune cell functions. This is in addition to its more established roles in the removal of misfolded, damaged, and effete proteins. This review examines the role of the Ub/proteasome system in processes underlying the classical effects of irradiation on cells, such as radiation-induced gene expression, DNA repair and chromosome instability, oxidative damage, cell cycle arrest, and cell death. Furthermore, recent evidence suggests that the proteasome is a redox-sensitive target for ionizing radiation and other oxidative stress signals. In other words, the Ub/proteasome system may not simply be a passive player in radiation-induced responses, but may modulate them. The extent of the modulation will be influenced by the functional and structural diversity that is expressed by the system. Cell types vary in the Ub/proteasome structures they possess and the level at which they function, and this changes as they go from the normal to the cancerous condition. Cancer-related functional changes within the Ub/proteasome system may therefore present unique targets for cancer therapy, especially when targeting agents are used in combination with radio- or chemotherapy. The peptide boronic acid compound PS-341, which was designed to inhibit proteasome chymotryptic activity, is in clinical trials for the treatment of solid and hematogenous tumors. It has shown some efficacy on its own and in combination with chemotherapy. Preclinical studies have shown that PS-341 will also potentiate the cytotoxic effects of radiation therapy. In addition, other drugs in common clinical use have been shown to affect proteasome function, and their activities may be valuably reconsidered from this perspective.
在过去几年中,泛素(Ub)/蛋白酶体系统越来越被认为是众多生理过程的调控者,这些生理过程包括信号转导、DNA修复、染色体维持、转录激活、细胞周期进程、细胞存活以及某些免疫细胞功能。此外,它在清除错误折叠、受损和衰老蛋白质方面发挥着更为确定的作用。本综述探讨了Ub/蛋白酶体系统在辐射对细胞的经典效应所涉及的过程中的作用,例如辐射诱导的基因表达、DNA修复和染色体不稳定性、氧化损伤、细胞周期停滞以及细胞死亡。此外,最近的证据表明蛋白酶体是电离辐射和其他氧化应激信号的氧化还原敏感靶点。换句话说,Ub/蛋白酶体系统可能不仅仅是辐射诱导反应中的被动参与者,而是可能对其进行调节。调节的程度将受到该系统所表现出的功能和结构多样性的影响。不同细胞类型所拥有的Ub/蛋白酶体结构及其功能水平各不相同,并且随着细胞从正常状态转变为癌变状态,这种情况也会发生变化。因此,Ub/蛋白酶体系统内与癌症相关的功能变化可能为癌症治疗提供独特的靶点,特别是当靶向药物与放疗或化疗联合使用时。旨在抑制蛋白酶体胰凝乳蛋白酶活性的肽硼酸化合物PS - 341正在进行治疗实体瘤和血源性肿瘤的临床试验。它自身以及与化疗联合使用时均已显示出一定疗效。临床前研究表明,PS - 341还将增强放射治疗的细胞毒性作用。此外,已证明其他常用临床药物会影响蛋白酶体功能,从这一角度重新审视它们的活性可能具有重要价值。